This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2023.
Program Description
Multiple targets specific to various cancers have led to the approval of several antibody-drug conjugates (ADCs) for the treatment of cancer, with many more under investigation. The engineering of an ADC has an important impact on its pharmacologic properties, mechanism of action, stability, efficacy, and toxicity in the treatment of solid tumors. As the utilization of ADCs in clinical practice increases, oncology pharmacists must remain informed about drug management strategies unique to each agent, including monitoring for efficacy and toxicity, management of adverse effects, preparation, dispensing, and administration. This program will explore the pharmacology of approved and emerging ADCs and their use as drug therapy across cancer types. Panelists will review patient cases in which audience participants will be able to practice developing patient-specific treatment plans with ADCs, with panelists sharing their expert perspectives on treatment and toxicity management.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 14, 2023
Expiration date: April 14, 2024
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the differences in pharmacologic properties among antibody-drug conjugates (ADCs) approved for the treatment of solid tumors
- Employ strategies for patients receiving ADCs to self-monitor and report adverse effects
- Illustrate appropriate preventive and/or treatment strategies in complicated ADC-related toxicity scenarios
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
